229 related articles for article (PubMed ID: 27746069)
1. Neuropsychiatric Complications of Parkinson Disease Treatments: Importance of Multidisciplinary Care.
Taylor J; Anderson WS; Brandt J; Mari Z; Pontone GM
Am J Geriatr Psychiatry; 2016 Dec; 24(12):1171-1180. PubMed ID: 27746069
[TBL] [Abstract][Full Text] [Related]
2. The impact and management of nonmotor symptoms of Parkinson's disease.
Lyons KE; Pahwa R
Am J Manag Care; 2011 Oct; 17 Suppl 12():S308-14. PubMed ID: 22087551
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological treatment of Parkinson disease: a review.
Connolly BS; Lang AE
JAMA; 2014 Apr 23-30; 311(16):1670-83. PubMed ID: 24756517
[TBL] [Abstract][Full Text] [Related]
4. Hyperdopaminergic behavioral spectrum in Parkinson's disease: A review.
Béreau M; Fleury V; Bouthour W; Castrioto A; Lhommée E; Krack P
Rev Neurol (Paris); 2018 Nov; 174(9):653-663. PubMed ID: 30224159
[TBL] [Abstract][Full Text] [Related]
5. Dopaminergic Therapies for Non-motor Symptoms in Parkinson's Disease.
Schaeffer E; Berg D
CNS Drugs; 2017 Jul; 31(7):551-570. PubMed ID: 28643183
[TBL] [Abstract][Full Text] [Related]
6. [Neuropsychiatric disorders in Parkinson's disease].
Noé-Sebastián E; Irimia-Sieira P; Pomares-Arias E; Martínez-Vila E; Luquin-Piudo MR
Rev Neurol; 2001 Apr 1-15; 32(7):676-81. PubMed ID: 11391498
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of parkinsonism and legal capacity].
Wallesch CW
Fortschr Neurol Psychiatr; 2011 Aug; 79(8):441. PubMed ID: 21809256
[No Abstract] [Full Text] [Related]
8. [Neuropsychiatric manifestations in Parkinson's disease].
Oikonomou E; Paparrigopoulos T
Psychiatriki; 2015; 26(2):116-30. PubMed ID: 26197101
[TBL] [Abstract][Full Text] [Related]
9. [Dopamine dysregulation syndrome in a patient with Parkinson's disease; a case report].
Hol WM; van der Zwaard R; Hovestadt A; van Megen HJ
Tijdschr Psychiatr; 2010; 52(4):259-63. PubMed ID: 20503167
[TBL] [Abstract][Full Text] [Related]
10. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders.
Voon V; Fernagut PO; Wickens J; Baunez C; Rodriguez M; Pavon N; Juncos JL; Obeso JA; Bezard E
Lancet Neurol; 2009 Dec; 8(12):1140-9. PubMed ID: 19909912
[TBL] [Abstract][Full Text] [Related]
11. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Parkinson Study Group
JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
[TBL] [Abstract][Full Text] [Related]
12. Medication-related impulse control and repetitive behaviors in Parkinson disease.
Voon V; Fox SH
Arch Neurol; 2007 Aug; 64(8):1089-96. PubMed ID: 17698698
[TBL] [Abstract][Full Text] [Related]
13. Neuropsychiatric Symptoms in Parkinson's Disease.
Aarsland D; Kramberger MG
J Parkinsons Dis; 2015; 5(3):659-67. PubMed ID: 26406147
[TBL] [Abstract][Full Text] [Related]
14. Disease-modifying strategies and challenges in PD: interactive breakout sessions.
Schapira AH
Neurology; 2003 Sep; 61(6 Suppl 3):S56-63. PubMed ID: 14504381
[No Abstract] [Full Text] [Related]
15. Behavioral, neuropsychiatric and cognitive disorders in Parkinson's disease patients with and without motor complications.
Solla P; Cannas A; Floris GL; Orofino G; Costantino E; Boi A; Serra C; Marrosu MG; Marrosu F
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1009-13. PubMed ID: 21324349
[TBL] [Abstract][Full Text] [Related]
16. A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs.
Poletti M; Logi C; Lucetti C; Del Dotto P; Baldacci F; Vergallo A; Ulivi M; Del Sarto S; Rossi G; Ceravolo R; Bonuccelli U
J Clin Psychopharmacol; 2013 Oct; 33(5):691-4. PubMed ID: 23857310
[TBL] [Abstract][Full Text] [Related]
17. Psychiatric symptoms screening in the early stages of Parkinson's disease.
Bugalho P; da Silva JA; Cargaleiro I; Serra M; Neto B
J Neurol; 2012 Jan; 259(1):124-31. PubMed ID: 21691730
[TBL] [Abstract][Full Text] [Related]
18. Drug treatments for the neuropsychiatric complications of Parkinson's disease.
Connolly BS; Fox SH
Expert Rev Neurother; 2012 Dec; 12(12):1439-49. PubMed ID: 23237351
[TBL] [Abstract][Full Text] [Related]
19. Compulsive use of dopamine replacement therapy: a model for stimulant drug addiction?
Ambermoon P; Carter A; Hall W; Dissanayaka N; O'Sullivan J
Addiction; 2012 Feb; 107(2):241-7. PubMed ID: 21793971
[TBL] [Abstract][Full Text] [Related]
20. Neuropsychiatric aspects of Parkinson disease psychopharmacology: Insights from circuit dynamics.
Butala A; Shepard M; Pontone G
Handb Clin Neurol; 2019; 165():83-121. PubMed ID: 31727232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
